(ECOR) Electrocore - Ratings and Ratios

ElectroCore, Inc. (NASDAQ:ECOR) is a bioelectronic medicine and wellness company specializing in non-invasive vagus nerve stimulation (VNS) technology. Its gammaCore platform, a handheld prescription device, targets acute pain associated with migraines, episodic cluster headaches, hemicrania continua, and paroxysmal hemicrania. The company also develops Truvaga for general health and wellbeing and TAC-STIM for human performance optimization. Its gammacore Sapphire device is a portable, reusable, rechargeable, and reloadable prescription solution for primary headache conditions. Founded in 2005, ElectroCore is headquartered in Rockaway, New Jersey, and operates in the U.S., U.K., and internationally.

As of the latest data, ElectroCore trades on the NASDAQ under the ticker symbol ECOR. The company falls under the Health Care Equipment sector, with a market capitalization of $101.31 million. Its current price stands at $14.93, with a 20-day average volume of 137,986 shares. Key metrics include a price-to-book ratio of 10.71 and a price-to-sales ratio of 4.34. The companys forward P/E is 0.00, reflecting its current growth stage and financial position.

3-Month Forecast - Month 1: ECOR is expected to test resistance at $16.61 (SMA 20) with support at $10.05 (SMA 200). Price action may remain range-bound due to moderate volatility (ATR: 1.28). - Month 2: If resistance at $16.61 is broken, upside targets include $18.50 and $20.00. Failure to breach this level may lead to consolidation or a pullback to $12.50. - Month 3: Longer-term trends suggest potential downside risk if the stock remains below its 20-day SMA. Support at $10.05 will be critical to maintaining bullish momentum. Fundamental factors, including revenue growth and profitability, will influence medium-term direction.